8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  September 15, 2010

CANTEL MEDICAL CORP.

(Exact name of registrant as specified in its charter)

Delaware	001-31337	22-1760285
(State or other jurisdiction	(Commission	(IRS Identification
of incorporation)	File Number)	Number)

150 Clove Road, Little Falls, New Jersey	07424
Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (973) 890-7220

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities  Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01              Regulation FD Disclosure

Attached hereto as Exhibit 99.1 is an investor presentation of Cantel Medical Corp. (the “Company”), which may be used in presentations by Company management to investors, analysts and others from time to time, including a presentation to be made on September 15, 2010.  The presentation will be posted on the Company’s website, www.cantelmedical.com. The information included in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Cantel Medical Corp. Investor Presentation – September 15, 2010

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CANTEL MEDICAL CORP.
	By:	/s/ Andrew A. Krakauer
		Andrew A. Krakauer
		President
Dated: September 15, 2010

3

Exhibit Index

Exhibit No.	Exhibit Description
99.1	Cantel Medical Corp. Investor Presentation – September 15, 2010

4

EX-99.1

Exhibit 99.1

 Cantel Medical Corp. (NYSE: CMN) Dedicated to Infection Prevention & Control 09-15-2010 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s filings and reports with the Securities and Exchange Commission. Such statements are only predictions, and actual events or results may differ materially from those projected. CROSSTEX

Cantel Medical Corp. ~$275M NYSE Leader in Infection Prevention & Control Expanding Global Awareness and Sensitivity to Infection Risk Large, growing market H1N1 (“Swine” Flu), MRSA, C.Diff, Staph Infections, etc. Leader in Infection Prevention & Control Niche Markets Medical device reprocessing, water purification and healthcare disposables Well balanced portfolio of synergistic products sold into numerous markets Recession buffered products 75% recurring revenue Disposables, disinfection/sterilization chemistries and service 14 synergistic acquisitions completed to shift product mix since 2001 Over 90% of products made in the USA Substantially higher EBITDA, EPS and cash flow Operating excellence including cost control, cost reductions and manufacturing efficiencies (including new MRP implementations) Focus on higher margin consumables and chemistries Sales and marketing investments across the board Specifically built direct U.S. hospital sales and service force in endoscope reprocessing PRODUCTS PERFORMANCE 2

Cantel Medical Corp. ~$275M NYSE Leader in Infection Prevention & Control Investing in significant upside growth opportunities Leverage our capabilities in high-value liquid chemical germicides and filters Organic and licensed R&D pipeline Major push started in FY’10 in chemistry development within and outside core business Greatly accelerate R&D investment in FY’11 to yield higher growth, higher margin, higher tech product innovations in FY’12 and beyond New markets - alternate channels Continue acquisition program using our strong balance sheet Proven integration model from product lines to standalone businesses Robust acquisition pipeline Solid manufacturing expertise in equipment, chemistries and disposables All within the FDA, EPA and international body regulatory environments Leveraged across all business units Highly experienced management team Significant insider (28%) and institutional ownership (49%) PROSPECTS PEOPLE 3

4 Cantel Medical Corp. $33B Global Infection Prevention & Control Market Global IP&C Market (2006 US$M) U.S. Infection Prevention & Control Market (US$B) Forecast CAGR% 2006-2016 = 3.9% Infections in Medical Facilities are a Rapidly Growing Problem Annually, 2.3 Million People Acquire Infections in U.S. Medical Facilities and 99,000 Die From Those Infections1 -- More than AIDS, Breast Cancer and Traffic Accidents Combined Globally, 50+% of ICU patients have infections associated with an increased risk of death1 Adds as much as $20 Billion in U.S. healthcare costs1 and $5.5 Billion in Insurance Costs2 Growing awareness of infection risk in professional and consumer psyche H1N1 (“Swine” Flu), MRSA, C.Diff, Staph Infections, etc 1 Infection Control Today, 12/1/2009 referencing the 12/2/2009 issue of JAMA. 2 Donald Wright M.D., M.P.H., Principal Deputy Assistant Secretary for Health, U.S. Department of Health and Human Services, December 2008. Centers for Disease Control and Prevention (CDC) as cited in Healthcare Purchasing News, November 2005, Vol.29, No.11. and “A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000”, Patricia Stone, RN, PhD. Data Source: Freedonia Market Research. 2009F Japan $2,040 6% Other Asia/Pac $2,110 7% Rest of the World $2,970 9% Canada & Mexico $920 3% United States $13,840 45% Western Europe $7,690 24% China $2,040 6% $0.0 $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 $16.0 $18.0 $20.0 $22.0 US$ Billions 2001 2006 2011 2016 Consumables & Disposables Equipment Services

5 Cantel Medical Corp. Niche Orientation of Infection Prevention & Control Markets 1 2 3 4 5 Brushes Disposable kits / trays Face shields Air filtration systems Aprons / bibs / arm protectors Dispensers Disposable medical products Masks Germicidal air cleaners Gloves Enzymatic cleaners Disposable surgical products Nurse/MD/Surg/Lab Hats Negative pressure isolation Lab gowns Medical device disinfectants Protection goggles Smoke evacuators Overshoes / coated boots Surface disinfectants Respirators Toxic gas detection systems Shirt jackets Wipes Wrap around lenses Water purification systems Surgical gowns 6 7 8 9 10 Autoclaves Antimicrobial linens Automated hand washers Adhesives / adhesive removers Antimicrobial catheters Chemical sterilizers Fluid control drapes Hand cleaners / soaps Antimicrobial dressings Blood pressure cuff covers EtO sterilizers General purpose drapes Hand sanitizers (waterless) Dressings Catheter securement devices Low temperature sterilizers Surgical drapes Drains / suction Dispenser boxes Medical device drying cabinets Hydrogel adhesive dressings Needle protection devices Medical device reprocessing Silver bandages / dressings Safety I.V. catheters Steam sterilizing units Surgical site skin prep Specimen transport bags Sterilization containers Sterilization packaging Washers / decontaminators Sterilization Services 11 12 13 14 15 Biological indicators Filtration systems Antimicrobial casters Antimicrobial paint Alert systems Chemical integrators Fluid control systems Cleaning carts Containment systems Handwashing EtO monitors Fluid warming systems Decontamination equip Washable keyboards Surveillance software Glutaraldehyde monitors Forced air warming Infectious waste bags Pest management Training Respirator fit testers Patient positioning Microfiber mops Rapid MRSA diagnostics Sterility assurance products Pressure mgmt systems Room decontaminators Temperature mgmt kits Sharps containers Solidifiers / Spill Kits Suction canister systems Waste management systems Disinfectants & Cleaners Disposables Masks / Headwear Air & Water Quality Protective Apparel Sterilization Drapes & Barrier Products Hand Hygiene Wound Care & Closures Needles / Sharps / Transport Quality Control & Testers Fluid / Temperature/ Positioning Medical Waste & Cleaning Equipment Environmental Surveillance / Software / Education

6 Cantel Medical Corp. Healthcare Reform Creates Greater Emphasis in IP&C Financial Penalties to Hospitals1 Preventable Readmissions – Estimated $25 billion cost to the system Beginning 2012, Medicare will stop paying hospitals for preventable readmissions tied to heart failure or pneumonia Beginning 2014, expand policy to cover four (4) more conditions Reduced Payment for Hospital Acquired Conditions – Infections & Errors Beginning 2012, Medicare will align actual payment to reported performance on patient satisfaction and care quality Beginning 2015, Dept. of Health & Human Services will start reporting each hospitals’ record for infections and medical errors pertaining to Medicare patients Payments reduced by 1% for those with highest rate of infections & medical errors No longer pay for treatment when a Medicaid patient is harmed during a hospital stay Despite Shrinking Budgets, Hospitals Maintain IP&C Funding2 2/3rds decreased or froze spending in 2009 and expect further cuts in 2010 However, virtually none cut patient safety infection control budgets in 2009, and spending growth is expected in the future 1 Healthcare Purchasing News, April 30, 2010. 2 HealthLeaders Media, April 6, 2010 – citation of LEK Hospital Purchasing Survey of January 2010 – Survey of 203 U.S. hospital CEOs, CFOs, COOs, materials managers, and purchasing directors.

7 Cantel Medical Corp. Three Synergistic Platforms - PRODUCTS Infection Prevention & Control Focus Healthcare & Life Sciences Orientation Reprocessing Systems Renal Dialysis & Endoscopy Minntech; Medivators Purification & Filtration Water Treatment & Therapeutic Filters Mar Cor Purification; Minntech Disposable Products Dental & Specialty Packaging Crosstex; Saf-T-Pak

8 Cantel Medical Corp. Well-Balanced Portfolio of PRODUCTS Last Twelve Months Ended April 30, 2010 (Q3’FY10)1 1 “All Other” includes Therapeutic Filtration Products and Specialty Packaging Products. 2 Before allocation of corporate expenses of ~$9.3M. 3 Earnings Before Interest, Taxes, Depreciation, Amortization, Stock Compensation Expense and Loss on Disposal of Fixed Asset. Net Sales $270.9M Operating Income $42.0M2 EBITDAS = $48.0M3 Healthcare Disposables $71.43 26% Dialysis $47.57 18% Endoscope Reprocessing $60.89 22% Water Purification & Filtration $74.73 28% All Other $16.32 6% Healthcare Disposables $13.62 32% Dialysis $10.56 25% Endoscope Reprocessing $6.45 15% Water Purification & Filtration $7.39 18% All Other $3.99 10%

z Cantel Medical Corp. Strong PERFORMANCE Over the Past Two Years 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Reflects abnormally large quarter due to Novel H1N1 (“Swine”) flu sales of facemasks. 3 Last Twelve Months Cash flow from Operations less Capital Expenditures divided by average shares outstanding. 4 Estimate is in comparison to Apr Q3’10 * Excluding $0.03 one-time charge from executive departure. LTM Free Cash flow = $1.30/share3 (Net Cash) July Q4’10 Est.4 2 9 Cash flow from Operations US Dollars Millions, except per share amounts Apr Jul Oct Jan Apr Jul Oct Jan Apr Q3'08 Q4'08 Q1'09 Q2'09 Q3'09 Q4'09 Q1'10 2 Q2'10 Q3'10 Net Sales $64.2 $64.3 $64.4 $62.4 $66.4 $66.8 $71.0 $66.6 $66.6 Gross Margin 34.7% 35.2% 36.7% 37.8% 38.4% 40.0% 41.5% 40.7% 40.1% EBITDAS1 $7.7 $8.0 $9.6 $9.9 $10.8 $11.7 $14.0 $11.9 $10.4 Operating Profit $4.2 $4.5 $6.2 $6.6 $7.2 $7.5 $10.4 $8.0 $6.9 Net Income $2.0 $2.6 $3.3 $3.8 $4.2 $4.3 $6.2 $4.9 $4.3 Diluted EPS $0.15 * $0.16 $0.20 $0.23 $0.25 $0.26 $0.37 $0.29 $0.25 Debt $63.8 $58.3 $57.3 $54.3 $49.3 $43.3 $38.0 $30.5 $25.0 Cash $19.3 $18.3 $15.7 $20.1 $22.3 $23.4 $23.1 $18.1 $19.2 Net Debt/(Cash) $44.5 $40.0 $41.6 $34.2 $27.0 $19.9 $14.9 $12.4 $5.8 Cash flow from Operations $8.8 $6.8 $5.4 $7.8 $8.1 $9.7 $6.5 $3.8 $7.1

10 Cantel Medical Corp. Significant Upside Growth Opportunities - PROSPECTS Substantial Sales & Marketing investments in core FY’09-FY’10 Substantial increase in R&D spending in FY’11 R&D/Technology – High-Margin Liquid Chemical Germicides (LCG) BIOSAFE® antimicrobial coating technology – starting with face masks Major investment in new chemistry development capabilities began mid-FY’10, accelerating in FY’11, to yield multiple New Product Introductions (NPI) in FY’12+ New business leader GM and senior marketing executive hired in March 2010 Identified and pursuing new liquid chemical germicides Expanded uses of existing chemistry products across all business segments Novel developments in fogging equipment and services Environmentally “Green” product orientation R&D/Technology – Equipment and Disposables Next generation water treatment equipment Numerous high value therapeutic filter developments underway Now also obtaining distribution rights to final product outside the USA Higher technology endoscope reprocessing equipment with new “single-shot” chemistry launched worldwide in FY’10 – further developments underway Unique healthcare disposables such as the Sure-Check® sterilization pouch

Cantel Medical Corp. Significant Upside Growth Opportunities - PROSPECTS New Markets – Alternative Channels Dedicated focus on corporate and government pandemic flu preparation One of only a few large U.S. manufacturers of FDA-cleared face masks Sponsored research study published demonstrating effectiveness of surgical facemasks vs. N-95 respirators (American Journal of Infection Control) Expanded hospital penetration with differentiated products and/or acquisition Specialized consumer markets Expand franchise internationally and raise current 18% of sales Good growth in Asia Acquisitions – Utilize Strong Balance Sheet Proven ability to integrate, leverage and grow acquired businesses Fourteen acquisitions in past nine years have reshaped Cantel Robust pipeline of opportunities Focus on disposables and water purification Pursue cross-divisional chemistry opportunities Add to international or hospital channels 11

12 Cantel Medical Corp. Experienced PEOPLE Andrew A. Krakauer President & CEO Former President of Ohmeda Medical (Division of Instrumentarium/GE) Over 20 years of healthcare experience Joined Cantel in 2004 as COO Craig A. Sheldon SVP, Chief Financial Officer & Treasurer Formerly with Ernst & Young LLP Certified Public Accountant Joined Cantel in 1994 Eric W. Nodiff SVP, General Counsel Former Partner at Dornbush Schaeffer Strongin & Venaglia, LLP Outside counsel to Cantel for 18 years Joined in-house in 2005 Seth R. Segel Executive Vice President Multiple years in Investment Banking / Strategy Consulting / Operations with Jupiter Media Metrix Joined Cantel in 2002 Roy Malkin President & CEO, Minntech Over 25 Years in Healthcare Curtis Weitnauer President & CEO, Mar Cor Over 20 Years in Water Treatment Gary Steinberg CEO, Crosstex Over 20 Years in Dental Products

13 Cantel Medical Corp. Segmentation Infection Prevention & Control Focus Healthcare & Life Sciences Orientation NYSE: CMN Renal / Dialysis Equipment, Sterilants, Consumables, Service Endoscope Reprocessing Equipment, Disinfectants, Consumables, Service Dental Disposables Water Purification Equipment, Field Service, Consumables Specialty Packaging Packaging, Training PURIFICATION & FILTRATION REPROCESSING DISPOSABLES Therapeutic Filtration Hollow Fiber Filters Dialysis Chains Hospitals Dental Offices Dialysis Clinics, Industrial Diverse Customer Set Hospitals, Biotech Firms Direct Sales Direct Sales Distributors Direct Sales & Distributors Direct Sales Distributors / OEM 2001 1 1996 4 2005 3 2003 7 2004 1 2001 1 Acquired

14 Cantel Medical Corp. Historical Income Statement Highlights 1 Reflects continuing operations and excludes any historical impact of Carsen Endoscopy & Surgical business. 2 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 3 Equivalent to “Income from Continuing Operations”. 4 Compound Annual Growth Rate. Continuing Operations Fiscal Years Ended July 311 US Dollars Millions, except per share amounts CAGR% 4 9 mo. 2004 2005 2006 2007 2008 2009 '04-'09 2010 LTM Net Sales $123.0 $137.2 $192.2 $219.0 $249.4 $260.1 16% $204.1 $270.9 Gross Profit $44.9 $53.9 $69.2 $79.0 $87.6 $99.5 17% $83.3 $110.0 EBITDAS2 $14.0 $19.4 $26.5 $28.6 $31.8 $42.0 25% $36.3 $47.8 Operating Profit $9.8 $14.2 $15.3 $16.8 $18.0 $27.5 23% $25.2 $32.7 Net Income3 $4.9 $7.9 $6.7 $8.1 $8.7 $15.6 26% $15.3 $19.6 Diluted EPS $0.32 $0.49 $0.41 $0.50 $0.53 $0.94 24% $0.90 $1.16

15 Cantel Medical Corp. Historical Balance Sheet Highlights 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Reclassified long-term debt as current liability due to expiration date of revolver. Continuing Operations: Fiscal Year Ended July 31 US Dollars Millions, except per share amounts Q3 2004 2005 2006 2007 2008 2009 2010 Total Assets $146.7 $165.3 $238.2 $263.7 $279.2 $277.9 $277.3 Current Ratio 2.7:1 2.2:1 2.1:1 2.1:1 2.2:1 2.3:1 2.5:12 Equity $86.5 $108.6 $140.8 $155.1 $168.7 $187.1 $206.2 Funded Debt to Equity 0.29 0.15 0.27 0.37 0.35 0.23 0.12 Gross Debt / LTM EBITDAS1 1.8x 0.8x 1.4x 2.0x 1.8x 1.0x 0.5x # of Shares Outstanding 14,612 15,005 15,399 16,116 16,371 16,644 16,856 LTM Net Sales per Share $8.42 $9.14 $12.48 $13.59 $15.23 $15.62 $16.07 LTM EBITDAS1 per Share $0.96 $1.28 $1.72 $1.77 $1.94 $2.52 $2.83

Cantel Medical Corp. Strategic Evolution 16 FY’04 – FY’08: Acquire and Define Infection Prevention & Control (ICP) Portfolio FY’09 – FY’10: Substantial Operational and P&L Improvement, while Investing in Sales & Marketing FY’11: Leverage Sales & Marketing and Drive R&D Investments. Close 1-2 Key Acquisitions EPS Range: $0.32-$0.53 EPS Range: $0.94-$1.16+ (incl. H1N1) $0.89-$1.03 (base business) FY’12+: Capitalize on all Strategic Investments (S&M, R&D, NPIs, Acquisitions) EPS Range: Significant Growth EPS Range: Moderate Base Business Improvement

17 Cantel Medical Corp. Strategic Objectives Remain Focused within Infection Prevention & Control Build a profitable $500 Million Specialty Business Invest in higher technology, higher margin and higher growth organic programs with near-to-mid-term payoff Orientation around Liquid Chemical Germicides (LCG’s) Capital Equipment / Consumable combination solutions Focus on channel expansion including flu preparation, hospital and international markets Substantial increased sales and marketing investments in base business Continue aggressive and proven acquisition program to leverage existing assets and channels to achieve strategic product and market goals Continue the program of Operational Excellence

Cantel Medical Corp. Summary Global, Growing $33B Market in Infection Prevention & Control Fragmented nature creates opportunities for further expansion ~$275M NYSE Specialty Infection Prevention & Control Leader 75% recurring revenue Selected for inclusion in the S&P SmallCap 600 Index Forbes 200 Best Small Companies in America (2009) Recession-buffered core business Strong cash flow and balance sheet Initiated $0.10/share annual dividend Substantial investment mode for new product development and increased sales and marketing capabilities 90+% of products are made in the USA Poised for Continued Organic and Acquired Growth with The right PRODUCTS, The right PERFORMANCE, The right PROSPECTS, The right PEOPLE. 18

 Cantel Medical Corp. (NYSE: CMN) Dedicated to Infection Prevention & Control CROSSTEX

Appendix Operating Segment Detail

21 Cantel Medical Corp. Three Strategic Platforms Reprocessing Systems Renal Dialysis & Endoscopy Minntech Purification & Filtration Water Treatment Mar Cor Purification; Minntech Disposable Products Dental & Specialty Packaging Crosstex; Saf-T-Pak Infection Prevention & Control Focus Healthcare & Life Sciences Orientation

22 Mar Cor Purification Process Water Value Comparison: Where We Participate Difficulty of water purification process Value Biologically Pure Water, Regulatory Impact Desalination Steam Generation Municipal drinking water Residential Medical Pharmaceutical Cosmetic/Topical Beverage Industrial Boiler Feed Commercial

Mar Cor Purification Suite of Offerings Equipment Services Consumables (filters & disinfectants) 60% 20% 20% 23

24 Mar Cor Purification (MCP) Commercial & Industrial Applications Filters & Sterilants (BSP Business) Medical / Dialysis Dialysis Water. #1 player. MCP installs a central system every business day 4-5% annual growth in patient population Mar Cor Purification Market Segments Small share, but pockets of strength Pharma, Research, Food & Beverage, Other High Purity $300M Market. Growing need for high purity water. BioScience Products: distribution channel for filter products, disinfection chemistries, and dry fog equipment. Growing need for environmentally safe disinfectants

25 Cantel Medical Corp. Three Strategic Platforms Reprocessing Systems Renal Dialysis & Endoscopy Minntech Filtration & Purification Water Treatment Mar Cor Purification; Minntech Disposable Products Dental & Specialty Packaging Crosstex; Saf-T-Pak Infection Prevention & Control Focus Healthcare & Life Sciences Orientation

26 Crosstex International Disposable Products – U.S. Dental Market Dental Consumables Market (Retail)1 Approximately 70% of North American Dental Expenditures U.S. $4.4 Billion, growing historically at 6-7%/year, now (2%)-0% Comparison: Physician Medical Supply Market = $19 Billion2 Global ~ $10.5 Billion Procedure Growth (hence consumables) has been Driven by Aesthetics and Specialty Procedures Examples include Braces, Whitening, Laminates, and Implants Growth in Core Preventative-Visit Dental Market 100 Million Americans Still Don't Visit a Dentist each Year ~125 Million Americans Still Have no Dental Insurance 1 NorthCoast Research, May 13, 2009 2 PSS World Medical 10-K. “[PSS’] primary focus is the $19 billion market for the distribution of medical products, medical equipment and office administered pharmaceutical products to physician offices, long-term care and assisted living facilities, and home healthcare providers and equipment dealers.

27 Crosstex International U.S. Dental Market Structure DENTISTS (156,000 Dentists / 120,000 Practices) (160,000 Hygienists / 200,000 Dental Assistants): 95+% Female DISTRIBUTORS Henry Schein (~40% share / 1,000 field reps / 90,000 sku’s (all prod.)) Patterson (~30% share / 1,550 field reps / 90,000 sku’s / 8-10% priv.label) Others (250+ local and regional players = acquisition targets of Schein & Patterson) MANUFACTURERS Top 10 have < 50% market share1 Patient Treatment Materials (PTM)2 #1 is Dentsply (3x size of #2/3 manufacturer (3M ESPE/Sybron)) Other Consumables with PTMs is a $4.4B growing historically at 6%, now flat Capital Equipment & Software (Growing historically at 10-12%/year, now (3%)-(2%)) 1 NorthCoast Research, May 13, 2009 2 Items include endodontic materials, prophy pastes/sealants, artificial teeth, crown/bridge materials, restoratives, carbide burs, hand pieces, ultrasonic scalers, impression materials, etc

28 Crosstex International Disposable Products Portfolio 100 % >65% Manufactured In-House 0% Towels Tray Covers Masks / Shields Sterilization Accessories Headrest / Barrier Covers Cups Gloves Needles / Sharps Chemicals / Liquids Convenience Products Cotton Products Ejectors / Evacuators Prophy Angles X-ray Barriers

29 Cantel Medical Corp. Three Strategic Platforms Reprocessing Systems Renal Dialysis & Endoscopy Minntech Filtration & Purification Water Treatment Mar Cor Purification; Minntech Disposable Products Dental & Specialty Packaging Crosstex; Saf-T-Pak Infection Prevention & Control Focus Healthcare & Life Sciences Orientation

30 Medivators Flexible Endoscopy – Market Description Colorectal Cancer – 2nd Leading Cause of Death from Cancer – Early Screening U.S. G.I. market ~ $150 Million1 Worldwide G.I. Market ~ $300 Million 8% CAGR forecast for next 10 years2 Worldwide markets expanding at greater rate “Manual” Reprocessing - Risky and Expensive Still ~ 10% of North American Market Still ~ 50% of International Markets Medivators investment in direct sales/service force (50+ people) and reprocessor R&D 1 Millennium Research Group, Toronto, Canada. Market defined as Automatic Endoscope Reprocessors + High-Level Disinfectants + Enzymatic Cleaners. 2 MedTech Insight

31 Medivators Flexible Endoscope Reprocessing – Full Product Range EQUIPMENT Automatic Endoscope Reprocessors Leak Testers Scope Buddy CONSUMABLES/ ACCESSORIES Hook-up kits Scope cabinets Water Filtration Vapor management Carts SERVICE Field Service Install T&M Contracts Depot Service and Service Parts DISINFECTANTS Rapicide Adaspor Detergents Wipes Broadest Array of Products and Services Individual Physician through to Large Teaching Hospital

32 Minntech Renal Renal Dialysis - Market Description Kidney Failure (End Stage Renal Disease) ~ 400,000 Patients in U.S.1 ~ 1,060,000 Patients Globally2 ~13% of American adults (26 million) have chronic kidney disease3 Kidney disease/failure is > 25% of Medicare’s annual expenditures3 Treatment Protocol 3x Per Week at a Specialized Facility for 3.5-5.0 Hours/Rx Reprocessing Sterilized “Re-Use” Dialyzers are Less Expensive Than “Single Use” Patient Growth Continues Direct Linkage of ESRD to Rising Incidence of Obesity, Diabetes and Hypertension 1 United States Renal Data System. 2 Artificial Organs 26(1):49-71, Blackwell Publishing, 2002 Int'l Society for Artificial Organs. 3 New York Times, 11/18/08, “Kidney Disease Takes a Growing Toll”

33 Minntech Renal Renal Dialysis - Products Renatron Automated Reprocessing System for Rinsing, Cleansing, Sterilizing and Testing Dialyzers for Multiple Use (Capital Equipment) Renalin Peracetic Acid-Based Sterilant Utilized with Renatron Equipment (Consumables) Dialysate Concentrates used During Hemodialysis Treatment to Clean the Blood (Consumables) Patient Treatment Products Cleaners Disinfectants Concentrates Monitoring Supplies, etc (Consumables)